Papadopoulou A - Search Results

1

Teriflunomide for oral therapy in multiple sclerosis.

Papadopoulou A, Kappos L, Sprenger T. Papadopoulou A, et al. Expert Rev Clin Pharmacol. 2012 Nov;5(6):617-28. doi: 10.1586/ecp.12.56. Expert Rev Clin Pharmacol. 2012. PMID: 23234322

2

Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis.

Radue EW, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Rudick RA, Lublin FD, Weinstock-Guttman B, Wynn DR, Fisher E, Papadopoulou A, Lynn F, Panzara MA, Sandrock AW; SENTINEL Investigators. Radue EW, et al. Among authors: papadopoulou a. J Neurol Sci. 2010 May 15;292(1-2):28-35. doi: 10.1016/j.jns.2010.02.012. Epub 2010 Mar 16. J Neurol Sci. 2010. PMID: 20236661 Clinical Trial.

3

Dimethyl fumarate for multiple sclerosis.

Papadopoulou A, D'Souza M, Kappos L, Yaldizli O. Papadopoulou A, et al. Expert Opin Investig Drugs. 2010 Dec;19(12):1603-12. doi: 10.1517/13543784.2010.534778. Epub 2010 Nov 11. Expert Opin Investig Drugs. 2010. PMID: 21067468 Review.

4

Evolution of MS lesions to black holes under DNA vaccine treatment.

Papadopoulou A, von Felten S, Traud S, Rahman A, Quan J, King R, Garren H, Steinman L, Cutter G, Kappos L, Radue EW. Papadopoulou A, et al. J Neurol. 2012 Jul;259(7):1375-82. doi: 10.1007/s00415-011-6361-x. Epub 2012 Jan 6. J Neurol. 2012. PMID: 22222856 Clinical Trial.

5

Contribution of cortical and white matter lesions to cognitive impairment in multiple sclerosis.

Papadopoulou A, Müller-Lenke N, Naegelin Y, Kalt G, Bendfeldt K, Kuster P, Stoecklin M, Gass A, Sprenger T, Radue EW, Kappos L, Penner IK. Papadopoulou A, et al. Mult Scler. 2013 Sep;19(10):1290-6. doi: 10.1177/1352458513475490. Epub 2013 Mar 4. Mult Scler. 2013. PMID: 23459568

6

Lesion-to-ventricle distance and other risk factors for the persistence of newly formed black holes in relapsing-remitting multiple sclerosis.

Papadopoulou A, Menegola M, Kuhle J, Ramagopalan SV, D'Souza M, Sprenger T, Radue EW, Kappos L, Yaldizli Ö. Papadopoulou A, et al. Mult Scler. 2014 Mar;20(3):322-30. doi: 10.1177/1352458513495583. Epub 2013 Jul 11. Mult Scler. 2014. PMID: 23846352 Clinical Trial.

7

The relationship between total and regional corpus callosum atrophy, cognitive impairment and fatigue in multiple sclerosis patients.

Yaldizli Ö, Penner IK, Frontzek K, Naegelin Y, Amann M, Papadopoulou A, Sprenger T, Kuhle J, Calabrese P, Radü EW, Kappos L, Gass A. Yaldizli Ö, et al. Among authors: papadopoulou a. Mult Scler. 2014 Mar;20(3):356-64. doi: 10.1177/1352458513496880. Epub 2013 Aug 19. Mult Scler. 2014. PMID: 23959709

8

Detection of cerebrospinal fluid leaks by intrathecal contrast-enhanced magnetic resonance myelography.

Papadopoulou A, Ahlhelm FJ, Ulmer S, Kappos L, Sprenger T. Papadopoulou A, et al. JAMA Neurol. 2013 Dec;70(12):1576-7. doi: 10.1001/jamaneurol.2013.744. JAMA Neurol. 2013. PMID: 24166493 No abstract available.

9

Intrathecal gadolinium for magnetic resonance myelography in spontaneous intracranial hypotension: valuable but may be risky--reply.

Papadopoulou A, Ahlhelm FJ, Sprenger T. Papadopoulou A, et al. JAMA Neurol. 2014 Jun;71(6):802-3. doi: 10.1001/jamaneurol.2014.577. JAMA Neurol. 2014. PMID: 24911131 No abstract available.

10

Safety of teriflunomide for the management of relapsing-remitting multiple sclerosis.

Papadopoulou A, Kappos L, Sprenger T. Papadopoulou A, et al. Expert Opin Drug Saf. 2015 May;14(5):749-59. doi: 10.1517/14740338.2015.1014795. Epub 2015 Feb 17. Expert Opin Drug Saf. 2015. PMID: 25687236 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

638 results

Search Page